Search Results for
“增加电报粉丝与订阅✅SMMFS.COM✅死粉tg粉,gNp”
March 26, 2014
Strontium ranelate (Protelos) is a drug approved for the treatment of osteoporosis in Europe, but not in Canada. It is effective in reducing fractures . Recently the European Medicines Agency […]
February 23, 2023
Updates on Bone Health:Physical activity and exercise Updates on Bone Health:Physical activity and exercise A continuing education program for those treating and training people with osteoporosis. Your presenters are: Barb […]
July 18, 2022
New FLS sites in BC and PEI The ongoing collaboration between The Brookfield Chair in Fracture Prevention and Osteoporosis Canada has resulted in a new program BreakFree – resulting in […]
January 22, 2008
Last week, Osteoporosis Canada heard a news story that suggested that there is an increased risk of developing osteonecrosis of bone if you are taking a bisphosphonate medication for osteoporosis. […]
January 29, 2024
Latest News Clinical Practice Guideline – Top 2023 Article on CMAJ.ca January 29, 2024 On October 10, 2023 a new guideline on the management of osteoporosis and fracture prevention was […]
January 12, 2024
Latest News IAB Membership Cycle Applications Being Accepted January 12, 2024 Canadian Institutes of Health Research (CIHR) The Canadian Institutes of Health Research (CIHR) is Canada’s federal funding agency for […]
![](https://osteoporosis.ca/wp-admin/admin-ajax.php?action=kernel&p=image&src=%7B%22file%22%3A%22wp-content%2Fuploads%2FWEBINAR-1-3-THE-DILEMMAS-OF-D.jpg%22%2C%22thumbnail%22%3A%22%2C%2C%22%7D&hash=85598597)
March 20, 2019
Vitamin D is a crucial nutrient for bone health. In this presentation Stephanie Atkinson, PhD discusses: Vitamin D –why do we need it? Does the new Canada’s Food Guide provide […]
April 8, 2019
GET SUPPORT Support Resources Osteoporosis Canada currently produces publications in various languages. LEARN MORE Let’s Talk The information line gives you access to trained and compassionate staff and volunteers who […]
July 14, 2009
We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]